Burning Rock Biotech (BNR) Common Equity (2019 - 2026)

Burning Rock Biotech's Common Equity history runs 8 years deep, the most recent figure standing at $74.9 million for Q1 2026.

• In Q1 2026, Common Equity fell 4.98% year-over-year to $74.9 million; the TTM figure through Mar 2026 stood at $74.9 million (down 4.98% YoY), while the FY2025 annual figure was $76.5 million, down 3.81% from the prior year.
• Common Equity for Q1 2026 stood at $74.9 million, down from $75.5 million in the prior quarter.
• The five-year high for Common Equity was $261.0 million in Q1 2022, with the low at $74.9 million in Q1 2026.
• The 5-year median for Common Equity is $99.3 million (2024), against an average of $122.5 million.
• The sharpest annual moves came in 2022 and 2026: Common Equity sank 43.57% in 2022, then retreated 4.98% in 2026.
• Burning Rock Biotech's Common Equity stood at $162.9 million in 2022, then slumped by 34.47% to $106.7 million in 2023, then declined by 24.23% to $80.9 million in 2024, then fell by 6.67% to $75.5 million in 2025, then decreased by 0.79% to $74.9 million in 2026.
• Business Quant data shows BNR's Common Equity at $74.9 million in Q1 2026, $75.5 million in Q4 2025, and $77.2 million in Q3 2025.